Citations

Clear

151 citation(s) found for "Soares, C".

Characteristics of patients with extracranial cervical artery dissections involving more than a single vessels: A subgroup analysis of STOP-CAD
Metanis, Issa, Akpokiere, Favour , Shu, Liqi , Jubran, Hamza , Antonenko, Kateryna, Rosa, Sara, Soares, Mafalda Delgado, Engelter, Stefan T. , Traenka, Christopher Kenan, Marto, João Pedro, Romoli, Michele, Zubair, Adeel , Omran, Setareh Salehi , Jubeh, Tamer , Shalabi, Fatma , Khan, Muhib, DeSousa, Diana Aguiar, Yaghi, Shadi, Leker, Ronen R., Sousa, Diana Aguiar de , Soares, Mafalda , Rosa, Sara , Jubran, Hamza , Engelter, Stefan T , Kaufman, Josefin E , Marto, João Pedro , Keser, Zafer , Aguiar de Sousa, Diana , Leker, Ronen R , Soares, Mafalda , Rosa, Sara , Metanis, Issa , Schwartzmann, Yoel , Antonenko, Kateryna , Heldner, Mirjam R. , Kaufmann, Josefin E. , Romoli, Michele , Keser, Zafer , Khan, Muhib , Yaghi, Shadi

Mayo Clinic

European Stroke Journal | January 20, 2026 | Volume: 11 | Issue: 1 | Pages: No page available

10.1093/esj/23969873251383313 | PMID 41614464 Get It

Abstract Introduction Cervical arterial dissections (CeAD) can involve either single (sCeAD) or multiple (mCeAD) arteries. Whether the involvement of a single versus multiple arteries is associated with outcomes remains unclear. We aimed to study associations between the number of affected arteries and clinical, imaging and outcome parameters. Patients and methods Patients with CeAD from the STOP-CAD multicenter registry study were included. Clinical, imaging, treatment and outcome parameters were compared between patients with sCeAD and mCeAD. Regression analyses were performed to identify associations with multi-arteries involvement. Results Overall, 3858 STOP-CAD patients were included in this analysis and 443 (11.5%) had mCeAD. The presence of mCeAD was associated with age (adjusted odds ratio [aOR] 95% confidence intervals [95% CI] 0.99; (0.98–1.00)), female sex (aOR 1.5; 95% CI 1.17–1.91), recent upper respiratory infection (aOR 2.25; 95% CI 1.55–3.27), presence of connective tissue disease (aOR 3.11; 95% CI 2.32–4.17), severe arterial stenosis (aOR 1.95; 95% CI 1.95–2.58), intracranial extension (aOR 1.47; 95% CI 1.04–2.09), vertebral artery involvement (aOR 2.50; 95% CI 1.94–3.22) and presence of dissecting aneurysm (aOR 2.59; 95% CI 1.95–3.42). In adjusted analyses, mCeAD was not associated with clinical outcomes (ischemic stroke, mortality, and sICH; all p > 0.05). Conclusions mCeAD does not appear to increase risk of subsequent stroke as compared to sCAD despite baseline risk factors suggestive of vasculopathy. mCeAD patients who did develop a stroke presented with milder strokes and less often had vessel occlusions compared to those with sCeAD. The presence of mCeAD did not impact outcomes.
Mechanical Dyssynchrony and Perfusion Heterogeneity Predict Adverse LV Remodeling in Patients with and without LBBB
Brandao, Simone Cristina Soares, Joseph, Lee , Brown, Jenifer M. , Lopez, Diana M. , Ramirez, Giselle Chiprez, Kavanagh, P A U L, Kriekinge, Serge D. Van , Liang, Joanna X., Builoff, Valerie , Divakaran, Sanjay, Weber, Brittany, Hainer, Jon, Carre, Sylvain , Blankstein, Ron, Dorbala, Sharmila, Le, Viet T., Mason, Steve, Chareonthaitawee, Panithaya, Wopperer, Samuel, Rosamond, Thomas, Berman, Daniel S., Dey, Damini, Carli, Marcelo F. Di, Slomka, Piotr J, Huck, Daniel, Soares Brandão, Simone Cristina , Divakaran, Sanjay , Slomka, Piotr J , Brown, Jenifer Michelle , Lopez, Diana, Lemley, Mark , Kavanagh, Paul , Weber, Brittany , Hainer, Jon , Blankstein, Ron , Dorbala, Sharmila , Le, Viet T. , Mason, Steve, Knight, Stacey , Chareonthaitawee, Panithaya , Wopperer, Samuel, Berman, Daniel S. , Dey, Damini , Carli, Marcelo F. Di , Huck, Daniel

Mayo Clinic

No container title available | January 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.09.26343726 | PMID 41646827 Get It

Abstract Aims Left bundle branch block (LBBB) is associated with mechanical dyssynchrony, heterogeneous perfusion, and adverse left ventricular (LV) remodeling. However, not all patients with LBBB develop cardiomyopathy, and dyssynchrony can occur without conduction defects. The role of microvascular dysfunction remains uncertain. We aimed to assess how mechanical dyssynchrony and perfusion heterogeneity relate to LV remodeling and function in patients with and without LBBB. Methods and results We retrospectively analyzed 233 patients with isolated LBBB and 932 matched controls who underwent PET myocardial perfusion imaging, assessing mechanical dyssynchrony (phase entropy), myocardial blood flow (MBF), coronary vascular resistance (CVR), myocardial flow reserve (MFR), septal-to-lateral MBF ratio (SLR) for perfusion heterogeneity, LV volumes, and ejection fraction (EF). Compared to controls, patients with LBBB had greater dyssynchrony (56% vs. 40%), larger LV volumes, and lower EF (54% vs. 67%) (all p <0.001), and had higher stress CVR (37 vs. 34 mmHg/mL·min⁻¹·g⁻¹), lower stress MBF (2.4 vs. 2.6 mL/min/g), reduced MFR (2.4 vs. 2.6), and lower SLR (0.95 vs. 1.00) (all p <0.05). Among patients with dyssynchrony, SLR<1.0 identified those with more adverse remodeling. In multivariable regression, phase entropy and SLR independently predicted LV volumes and EF, with adverse effects of SLR reduction amplified in LBBB (interaction p <0.01). In the Cox proportional hazards analysis, phase entropy (HR:1.02, p =0.01), MFR (HR:0.62, p <0.001), and LVEF (HR:0.97, p <0.001) were independently associated with mortality and heart failure hospitalization, whereas LBBB was not. Conclusions Mechanical dyssynchrony and perfusion heterogeneity independently predict adverse LV remodeling, irrespective of LBBB. Integrated imaging enhances cardiomyopathy stratification.
A phase 1 first-in-human, dose-escalation and -expansion study of RYZ401, a novel radiopharmaceutical therapy (RPT) labeled with actinium-225 ( 225 Ac), in patients with neuroendocrine tumors (NETs) and ot
WONG, R, Anthony, Lowell , Kaván, Petr, Ramirez, R, Allen-Auerbach, Martin S, Prasad, Vikas , Osman, Medhat, Starr, Jason S., Patel, Dipen Chandrakant, Ferreira, Denis Vasconcelos, Susnow, Roberta, Wang, Xuemei, Soares, Heloisa P. , Ramirez, Robert A., Reilley, Matthew J. , Osman, Medhat, Sonbol, Mohamad Bassam , Hálfdánarson, Þorvarður R. , Starr, Jason S. , Singh, Simron

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: No page available

10.1200/jco.2026.44.2_suppl.tps646 Get It

TPS646 Background: SSTR-targeted RPT has transformed the treatment landscape for NETs, significantly improving clinical outcomes in phase 3 studies versus other targeted therapies. Nevertheless, disease progression and renal toxicity after treatment highlight the need for further improvement. Use of the α-emitter 225 Ac as the radioactive component has shown promising results in clinical studies: initial data from ACTION-1 suggest promising efficacy for RYZ101, a first-in-class, highly potent α-emitting RPT, in patients with SSTR+ GEP-NETs progressing after 2–4 cycles of 177 Lu-somatostatin analogs. RYZ401 is a cyclic 6-amino acid SSTR-targeting peptide agonist conjugated to a DOTA chelator bound to 225 Ac. Preclinical data have shown an improved therapeutic window versus DOTATATE. RYZ401 has the potential to deliver higher radiation doses to tumors, with improved renal clearance and lower kidney absorbed dose, potentially eliminating the need for amino acid infusion. Methods: RYZ401-101 is a global, multicenter, phase 1, first-in-human, dose-escalation/-expansion study designed to determine the recommended phase 2 dose (RP2D) and optimal treatment regimen, safety and tolerability, and preliminary efficacy of RYZ401 in patients with NETs and other selected solid tumors expressing SSTRs. Key eligibility criteria: histologically confirmed metastatic or unresectable well-differentiated NETs; WHO grade 1–3 (Ki-67 ≤55%); ≥1 SSTR PET-positive measurable lesion; and disease progression after ≥1 prior treatment line. In dose escalation, 6–18 patients will receive escalating doses of RYZ401 (2.0–11.1 MBq IV Q6W × 2–4 cycles); no amino acid co-infusion is planned. In dose expansion, approximately 80 patients will receive RYZ401 at the RP2D, 40 patients with well-differentiated GEP-NETs (cohort A) and 40 with other SSTR+ tumors including non-GEP-NETs (cohort B). Primary endpoints: dose-limiting toxicities in weeks 1–4 of treatment (dose escalation) and safety (dose expansion). Secondary endpoints: safety, pharmacokinetics, and efficacy outcomes (dose escalation and expansion). RYZ401 dosimetry will be evaluated in a sub-study of 10−16 patients. Enrollment is ongoing in the USA. Clinical trial information: NCT07165132 .
Recurrent Cervical Artery Dissection Prevalence and Predictors: A Secondary Analysis of the STOP-CAD Study
Marto, João Pedro, Shu, Liqi , Wu, Eileen , Mendel, Daniel M., Heldner, Mirjam R. , Kaufmann, Josefin E. , Leker, Ronen R., Zedde, Marialuisa, Nehme, Ahmad , Muppa, Jayachandra , Sousa, Diana Aguiar de, Sousa, João André, Fonseca, Ana Catarina , Nzwalo, Hipólito , Romoli, Michele, Omran, Setareh Salehi , Keser, Z, Kam, Wayneho , Zubair, Adeel , Velez, Faddi G. Saleh, Elangovan, Cheran, Krishnaiah, Balaji , Metanis, Issa, Siegler, James E., Rothstein, Aaron, Khazaal, Ossama , Antonenko, Kateryna, Lester, Evan, Crandall, Ross , Rosa, Sara, Soares, Mafalda Delgado, Bakradze, Ekaterina, Ghannam, Malik , Elnazeir, Marwa , Klein, Piers, Traenka, Christopher , Henninger, Nils, Nguyen, Thanh N., Yaghi, Shadi, Zedde, Marialuisa , Henninger, Nils , Marto, João Pedro , Mandel, Daniel , Sousa, Diana Aguiar de , Soares, Mafalda , Marto, João Pedro , Wu, Eileen , Mandel, Daniel M , Leker, Ronen R , Zedde, Marialuisa , Aguiar de Sousa, Diana , Sousa, Joao Andre , Romoli, Michele , Salehi Omran, Setareh , Keser, Zafer , Bavarsad Shahripour, Reza , Kam, Wayneho , Zubair, Adeel , Saleh Velez, Faddi , Elangovan, Cheran , Krishnaiah, Balaji , Metanis, Issa , Pascarella, Rosario , Siegler, James E , Rothstein, Aaron , Khazaal, Ossama , Antonenko, Kateryna , Simpkins, Alexis N , Crandall, Ross , Rosa, Sara , Soares, Mafalda , Bakradze, Ekaterina , Willey, Joshua , Ghannam, Malik , Samaniego, Edgar A , Elnazeir, Marwa , Klein, Piers , Traenka, Christopher , Henninger, Nils , Nguyen, Thanh N , Engelter, Stefan T , Yaghi, Shadi , Muppa, Jayachandra , Heldner, Mirjam R , Kaufman, Josefin E , Fonseca, Ana Catarina , Nzwalo, Hipolito , Nehme, Ahmad , Keser, Zafer , Shahripour, Reza Bavarsad , Velez, Faddi G. Saleh , Elangovan, Cheran , Metanis, Issa , Pascarella, Rosario , Siegler, James E. , Rothstein, Aaron , Simpkins, Alexis N. , Bakradze, Ekaterina , Klein, Piers , Nguyen, Thanh N. , Engelter, Stefan T. , Yaghi, Shadi

Mayo Clinic

Stroke | January 12, 2026 | Volume: 57 | Issue: 4 | Pages: 876-882

10.1161/strokeaha.125.053299 | PMID 41521918 Get It

BACKGROUND: Patients with cervical artery dissection (CeAD) may experience a recurrent dissection, but its frequency, risk factors, and clinical implications are not well defined. We aimed to determine the risk, associated factors, and clinical impact of recurrent CeAD. METHODS: The STOP-CAD study (Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection) was a multicenter international retrospective observational study of patients with CeAD treated between January 2015 and June 2022. Recurrent dissection was defined as a CeAD occurring at least 7 days after the diagnosis of the index event that affects a different artery or a different segment of the same artery. Patients were followed from day 7 up to 2 years. The absolute risk of recurrent CeAD over time was calculated using Kaplan-Meier survival estimates. Multivariable logistic and Cox regression models were used to assess predictors of CeAD recurrence. RESULTS: Of the 4023 patients included in STOP-CAD, 3836 (median age 46 years, 45% women) were eligible for this analysis. During a median (interquartile range) follow-up of 295 (97–720) days, 88 (2.29%) patients had a CeAD recurrence. Median time-to-recurrent CeAD was 53 (interquartile range, 18–157) days. The estimated risk of recurrent CeAD at 2 years was 3.22% (95% CI, 2.59%–4.00%). In multivariable analyses, younger age (adjusted odds ratios, 0.98 [95% CI, 0.96–0.99]), migraine (adjusted odds ratio, 1.88 [95% CI, 1.14–3.07]), and fibromuscular dysplasia (adjusted odds ratio, 2.90 [95% CI, 1.66–5.06]) were associated with CeAD recurrence, while presenting with an ischemic stroke was associated with a lower likelihood of recurrence (adjusted odds ratio, 0.47 [95% CI, 0.29–0.75]). These associations with CeAD recurrence over time were confirmed by Cox regression analyses. Among the 88 patients with recurrent CeAD, only 5 had accompanying ischemic events (3 strokes, 2 transient ischemic attacks). CONCLUSIONS: In this retrospective study, recurrent CeAD was uncommon, approximately half of the events were diagnosed within the first 2 months of the index event, and recurrent events rarely caused new ischemic events. Younger age, migraine, absence of ischemic stroke at presentation, and signs of fibromuscular dysplasia may help identify high-risk patients.
PART characterization using MK‐6240 and Flortaucipir
Soares, Carolina, Ferreira, Pamela C.L., Madeiros, Marina Scop, Rocha, Andreia, Bellaver, Bruna, Oliveira, Markley Silva , Povala, Guilherme, Amaral, Lívia , Masdeu, Joseph C., Tudorascu, Dana L, Karikari, Thomas K, Soleimani‐Meigooni, David N., Fortea, Juan M., Lowe, VJ, Oh, Hwamee, Pascual, Belen, Gordon, Brian A., Rosa‐Neto, Pedro, Baker, Suzanne L. , Pascoal, Tharick A, Medeiros, Marina Scop , Soares, Carolina , Ruppert, Emma Patrice , Ferreira, Pâmela C.L. , Madeiros, Marina Scop, Rocha, Andreia, Rodrigues, Matheus Scarpatto , Bellaver, Bruna , Povala, Guilherme , Lussier, Firoza Zubeida , Masdeu, Joseph C , Tudorascu, Dana , Karikari, Thomas K. , Soleimani‐Meigooni, David N. , Fortea, Juan , Oh, Hwamee , Pascual, Belén , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 11, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_106723 Get It

Abstract Background Older adults with brain tau pathology but no evident amyloid‐beta (A) pathology can be referred to as primary age‐related tauopathy (PART). However, in vivo characterization of PART using biomarkers remains unclear, varying based on the method used to define tau pathology (e.g. different tau‐PET tracers). Here, we conducted a head‐to‐head characterization of PART using two different tau‐PET tracers. Method We studied 433 individuals from the HEAD cohort (244 CU, 138 MCI, and 51 with dementia). Participants underwent clinical assessments, MRI, A‐PET, both MK‐6240 and Flortaucipir scans, and a subset with plasma biomarkers ( n = 332). A‐PET positivity was defined as Centiloid>24. Tau‐positivity(T) was determined by MK‐6240 and Flortaucipir SUVR values exceeding the mean+2SD in at least one Braak region anchored in CU A‐ individuals followed by visual confirmation in A‐/T+ cases. Concordance across biomarkers was assessed among PART (A‐/T+), A‐/T‐ and A+/T+ groups. Plasma GFAP, p ‐tau217, NFL levels, and Centiloids were compared across A/T groups using linear regression. Result We found a total of 25 (5.8 %) cases classified as A‐/T+ defined by at least one tau tracer (74±6.3 years, 52% females, 17 CU, 3 MCI, 5 with dementia). Detection of A‐/T+ cases varied by tracer: MK‐6240( n = 20), Flortaucipir( n = 16) (Figure 1A). Among A‐/T+ individuals, MK‐6240 identified 13 CU, 4 MCI, and 3 dementia cases, while Flortaucipir identified 11 CU, 3 MCI, and 2 dementia cases(Figure 1B). Concordance between MK‐6240 and Flortaucipir in A‐/T+ cases was low ( n = 11, 44%)(Figure 1C). A‐/T+ individuals showed no significant biomarker differences from A‐/T‐ but had lower biomarker levels than A+/T+: Centiloids (MK‐6240: T=15.08, p <0.001; Flortaucipir: T=14.36, p <0.001), GFAP (MK‐6240: T=5.04, p < 0.01; Flortaucipir: T=2.92, p <0.001), p ‐tau217 (MK‐6240: T=7.77, p <0.001; Flortaucipir: T=6.34, p <0.001), except for NFL (MK‐6240: T=1.35, p = 0.18; Flortaucipir: T=1.14, p = 0.25)(Figure 2). Representative A and tau biomarker cases (Figure 3A), along with discordant cases classified as T+ by only one tracer (Figure 3B), are illustrated. Conclusion Our preliminary analysis revealed a higher prevalence of A‐/T+ cases with MK‐6240 than Flortaucipir, low concordance between tracers and consistently lower biomarker levels in A‐/T+ compared to A+/T+. Larger studies and longitudinal analyses are necessary to ascertain the pathological trajectories of A‐/T+ individuals with varying tau biomarker profiles.
Head‐to‐Head evaluation of plasma p ‐tau217 associations with MK6240, Flortaucipir, PI2620, and RO948 tau PET tracers
Ferreira, Pamela C.L., Chan, Tevy , Bellaver, Bruna, Povala, Guilherme, Soares, Carolina, Felix, Cynthia, Rocha, Andreia, Madeiros, Marina Scop, Amaral, Lívia , Cehula, Juli, Masdeu, Joseph C., Tudorascu, Dana L, Karikari, Thomas K, Soleimani‐Meigooni, David N., Fortea, Juan M., Lowe, VJ, Oh, Hwamee, Pascual, Belen, Gordon, Brian A., Rosa‐Neto, Pedro, Baker, Suzanne L. , Pascoal, Tharick A, Medeiros, Marina Scop , Ferreira, Pâmela C.L. , Bellaver, Bruna , Povala, Guilherme , Bauer‐Negrini, Guilherme , Ruppert, Emma Patrice , Soares, Carolina , Felix, Cynthia , Rocha, Andreia, Madeiros, Marina Scop, Cehula, Juli, Lussier, Firoza Zubeida , Masdeu, Joseph C , Tudorascu, Dana , Karikari, Thomas K. , Soleimani‐Meigooni, David N. , Fortea, Juan , Oh, Hwamee , Pascual, Belén , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 11, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_106115 Get It

Abstract Background Tau phosphorylation and aggregation are hallmark features of Alzheimer's disease pathology(AD). Previous studies have shown that plasma phosphorylated tau( p ‐tau) at threonine 217 can detect AD‐related tau tangle pathology. However, the head‐to‐head association between p ‐tau217 and different tau PET tracers remains unexplored. Here, we conducted a head‐to‐head comparison of the association between plasma p ‐tau217 and four distinct tau PET tracers[MK6240, Flortaucipir(FTP), PI2620, RO948]. Method We studied 338 individuals across the AD continuum from the HEAD study[190 cognitively unimpaired elderly(CU), 109 with mild cognitive impairment(MCI), and 39 with dementia] with available FTP, MK6240, and plasma p ‐tau217 measured by ALZpath assay. A subset of 64 individuals(28 CU, 25 MCI, and 11 dementia) also had PI2620 and RO948, and p ‐tau217 measured by Lumipulse. The strength of the association was determined using t‐value maps from regression models testing the association between each tau PET tracer and plasma p ‐tau217, and the extent was measured by the percentage of significant voxels(t‐value>3.2). R‐square metric was used to determine how much of the variance in tau PET tracer estimates was explained by plasma p ‐tau217 concentrations. Associations between p ‐tau217 with tau PET were evaluated using the Spearman test. Result We found that in CU, both the extent and magnitude of the association with plasma p ‐tau217 were higher for MK6240 compared to FTP (Figure 1A‐D). Plasma p ‐tau217 explained a greater proportion of the variance in MK6240 than in FTP (Figure 1E‐F). In CI, the extent and magnitude of the association were similar for MK6240 and FTP. Additionally, plasma p ‐tau217 explained a similar proportion of the variance in MK6240 and FTP. Using the subset of individuals who had all tau tracers, MK6240 showed a slightly higher extent of association with p ‐tau217, followed by FTP, PI2620, and RO948 (Figure 2A‐B). The magnitude of association was stronger for MK6240, followed by PI2620, RO948, and FTP (Figure 2C‐D). Plasma p ‐tau217 explained a greater proportion of the variance in MK6240, followed by FTP, RO948, and PI2620 (Figure 2E‐F). We compared the associations between different p ‐tau217 assays, and both assays presented similar associations with all tau PET tracers (Figure 3). Conclusion In summary, our results indicate that the four tau PET tracers exhibit robust associations with plasma p ‐tau217 in similar topographical regions.
Tau exacerbates the development of motor disturbances but has no effect on the development of irritability across the Braak stages – The HEAD Study
Povala, Guilherme, Ferreira, Pamela C.L., Amaral, Lívia , Soares, Carolina, Medeiros, Marina Scop , Ferrari‐Souza, João Pedro, Bellaver, Bruna, Zalzale, Hussein, Zimmer, Eduardo R., Tudorascu, DL, Pascual, Belen, Gordon, Brian A., Lowe, VJ, Oh, Hwamee, Soleimani‐Meigooni, David N., Rosa‐Neto, Pedro, Baker, Suzanne L. , Pascoal, Tharick A, Pascual, Belén , Pascual, Belen , Aguzzoli, Cristiano Schaffer , Povala, Guilherme , Ferreira, Pâmela C.L. , Lussier, Firoza Zubeida , Bauer‐Negrini, Guilherme , Soares, Carolina , Ferrari‐Souza, João Pedro , Bellaver, Bruna , Rohden, Francieli , Leffa, Douglas Teixeira , Schilling, Lucas Porcello , Zimmer, Eduardo Rigon , Tudorascu, Dana , Gordon, Brian A. , Oh, Hwamee , Soleimani‐Meigooni, David N. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 10, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_105322 Get It

Abstract Background Previous studies demonstrated an association between tau pathology and the development of neuropsychiatric symptoms (NPS) in individuals with Alzheimer's disease (AD). However, the extent to which tau influences each specific NPS domain remains unclear. Here, we aim to investigate the association of tau and each NPS domain in the AD continuum. We hypothesized that tau plays a comparatively greater effect on the emergence of hyperactive and psychotic symptoms compared to other NPS domains. Method We assessed 385 individuals (216 cognitively unimpaired (CU), 128 MCI, and 41 AD dementia) from the HEAD study who underwent clinical assessments with the Neuropsychiatry Inventory Questionnaire (NPI‐Q) and had positron emission tomography (PET) for amyloid‐β (Aβ) ([ 18 F]AZD4694 or [ 11 C]PiB), and tau tangles ([ 18 F]MK6240) at the same visit. Tau SUVR values were tailored with a mask from Braak stages I‐VI, using the inferior cerebellar gray matter as a reference region. All individuals with dementia had a positive Aß‐PET. Voxel‐wise and Tobit censored regression tested the association between NPS domains and biomarkers accounting for age, sex, cognitive status, and study site. We used censored regression models to account for skewed data alongside a leave‐one‐out (loo) approach to identify which NPS domains most contributed to results. Result CI individuals had significantly higher NPI‐Q scores and Tau PET SUVR than CU (Figure 1A, 1B). NPI‐Q score was significantly associated with tau‐PET predominantly in fronto‐parietal regions. Removing irritability from the models strengthened this association (Figures 2A‐C). Regression loo models revealed that motor disturbances contributed most to the association between NPS and tau‐PET across all Braak stages. Notably, irritability had a negative effect on the association in all Braak stages, suggesting that tau does not play a role in the development of irritability and is highly associated with motor disturbances (Figure 3). Conclusion Our study suggests that tau contributes to the development of motor disturbances but has no effect on the development of irritability across the AD continuum. These findings provide additional rationale for the development of new therapeutics aiming to mitigate motor disturbances and irritability in AD patients.
Head‐to‐head in vivo Braak staging with MK6240 and Flortaucipir
Rocha, Andreia, Bellaver, Bruna, Madeiros, Marina Scop, Soares, Carolina, Ferreira, Pamela C.L., Povala, Guilherme, Amaral, Lívia , Masdeu, Joseph C. , Tudorascu, DL, Soleimani‐Meigooni, David N., Fortea, Juan M., Lowe, VJ, Oh, Hwamee, Pascual, Belen, Gordon, Brian A., Rosa‐Neto, Pedro, Baker, Suzanne L. , Pascoal, Tharick A, Pascual, Belén , Medeiros, Marina Scop , Pascual, Belen , Rocha, Andreia, Bellaver, Bruna , Ruppert, Emma Patrice , Madeiros, Marina Scop, Soares, Carolina , Ferreira, Pâmela C.L. , Povala, Guilherme , Bauer‐Negrini, Guilherme , Lussier, Firoza Zubeida , Rodrigues, Matheus Scarpatto , Masdeu, Joseph C , Tudorascu, Dana , Soleimani‐Meigooni, David N. , Fortea, Juan , Oh, Hwamee , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 9, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_107534 Get It

Abstract Background In vivo Braak staging stratifies patients across the AD spectrum and has the potential to harmonize tau PET tracer staging. This study aims to compare and test harmonization procedures for Braak staging individuals using MK6240 and Flortaucipir tau PET tracers. Methods We assessed 437 participants across the AD spectrum (245 cognitively unimpaired (CU) and 192 cognitively impaired; mean age 68.5 ± 8.6) using head‐to‐head MK6240 and Flortaucipir scans. We computed SUVRs in Braak regions of interest (ROIs) and assessed four cut‐off methods for Braak positivity: (a) mean + 2.5 SD of young controls (age <28 years), (b) mean + 2.5 SD of elderly CU Aβ−, (c) Gaussian mixture modeling (GMM), and (d) the Youden index. Braak stages were assigned using seven (0 to VI) or four (0, I–II, III–IV, V–VI) categories. We evaluated inter‐ and intra‐tracer concordance (intra‐tracer, i.e., whether it follows the sequential Braak pattern). Results The intra‐tracer seven‐class Braak staging concordance ranged from 63% to 94%. With the highest intra‐tracer Braak concordance being achieved when using GMM cutoffs: 94% (MK6240) and 89% (Flortaucipir; Figure 1). Inter‐tracer agreement concordance ranged from 56% to 76%. The highest concordance emerged from the CU Elderly Aβ– cutoff optimizing the Braak II region for spill‐off (Figure 2). Using the Braak staging simplified version improved intra‐tracer concordance in both tracers (MK6240as well as inter‐tracer agreement (86.5%). Most inter‐tracer discrepancies were observed at Braak stages II–IV. Despite showing staging discordances, the distribution of cognitive status across the Braak stages is similar for both tracers (Figure 3). Conclusion These preliminary findings reveal some discrepancies in Braak staging when comparing MK6240 and Flortaucipir. Our results also suggest that adjustments in cutoffs and regions of interest can partially mitigate both inter‐ and intra‐tracer divergences. Finally, our analysis suggests robust concordance after adjustment and using 4 classes (0, I‐II, III‐IV, V‐VI).
Defining tau PET positivity grey zones for MK6240 and Flortaucipir quantification
Povala, Guilherme, Bellaver, Bruna, Medeiros, Marina Scop , Amaral, Lívia , Ferreira, Pamela C.L., Soares, Carolina, Tudorascu, DL, Finn, Quentin, Masdeu, Joseph C., Oh, Hwamee, Fortea, Juan M., Soleimani‐Meigooni, David, Lowe, Val J. , Gordon, Brian A., Pascual, Belen, Rosa‐Neto, Pedro, Baker, Suzanne L. , Pascoal, Tharick A, Povala, Guilherme , Bellaver, Bruna , Bauer‐Negrini, Guilherme , Ruppert, Emma Patrice , Lussier, Firoza Zubeida , Ferreira, Pâmela C.L. , Soares, Carolina , Tudorascu, Dana , Masdeu, Joseph C , Oh, Hwamee , Fortea, Juan , Soleimani‐Meigooni, David N. , Gordon, Brian A. , Pascual, Belén , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 8, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_106847 Get It

Abstract Background Tau PET measures are inherently continuous and applying dichotomized thresholds introduces conceptual and analytical idiosyncrasies. Understanding the limitations in the transition from tau‐negative to tau‐positive classifications is crucial for the effective use of these thresholds. This study aims to determine the confidence levels of tau PET thresholds of abnormality for different tau PET tracers by characterizing their “gray zone” using the universal tau PET scale (Uniτ, www.unitau.app ). Method We evaluated 485 individuals across the aging and AD spectrum from the HEAD study, with head‐to‐head scans for MK6240 and Flortaucipir. Uniτ estimates were derived from the Meta‐Temporal ROI. Tau positivity (T+) was defined as Uniτ values exceeding the mean plus 3 SD of individuals younger than 28 years ( n = 24). Two physicians independently performed a visual assessment of tau positivity for each tracer, with agreement indicating clear tau pathology (TVR+). Logistic regression was used to estimate the probability of TVR+ across Uniτ values for each tracer ( n = 189, CU elderly Aβ‐ and CI Aβ+). Individuals were classified as negative, positive, or within a “gray zone” between the most liberal T+ threshold and varying TVR+ probability thresholds (50%, 75%, 90%, 95%, and 99%). Result The Uniτ gray zone, defined as a function of TVR+ probabilities, demonstrated consistency between the two tracers, with differences observed only in the decimal range. The most liberal Uniτ threshold for T+ was 11.0 for both MK6240 and Flortaucipir, closely matching the 50% TVR+ probability threshold (11.1 for MK6240 and 11.7 for Flortaucipir). Higher TVR+ probabilities corresponded to increased Uniτ values with MK6240 and Flortaucipir showing near‐identical values between the tracers: 14.2 and 14.8 for 75%, 17.3 and 17.9 for 90%, 19.4 and 19.9 for 95%, and 24.1 and 24.6 for 99%, respectively (Figure 1). In total, 26 participants fell within the gray zone for MK6240, compared to 47 participants for Flortaucipir. Conclusion These findings highlight the potential of Uniτ to provide a standardized approach for assessing tau positivity across tracers. By combining quantitative Uniτ measures with visual assessments, we enhance the understanding of tau positivity certainty, particularly in the transition between negative and positive classifications.
Tau‐PET and plasma GFAP association in cognitively unimpaired Aβ‐PET negative individuals
Saha, Pampa , Povala, Guilherme, Ferreira, Pamela C.L., Amaral, Lívia , Karikari, Thomas K, Oliveira, Markley Silva , Rocha, Andreia, Felix, Cynthia, Medeiros, Marina Scop , Soares, Carolina, Masdeu, Joseph C. , Tudorascu, Dana , Soleimani‐Meigooni, David, Fortea, Juan M., Lowe, Val J. , Oh, Hwamee , Gordon, Brian A., Rosa‐Neto, Pedro, Baker, Suzanne L. , Bellaver, Bruna , Povala, Guilherme , Ferreira, Pâmela C.L. , Bauer‐Negrini, Guilherme , Lussier, Firoza Zubeida , Karikari, Thomas K. , Rodrigues, Matheus Scarpatto , Felix, Cynthia , Ruppert, Emma Patrice , Soares, Carolina , Masdeu, Joseph C , Soleimani‐Meigooni, David N. , Fortea, Juan , Pascual, Belén , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 8, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_105935 Get It

Abstract Background We showed that astrocyte reactivity, as measured by plasma GFAP levels, influences Aβ mediated tau PET pathology in cognitively unimpaired (CU) Aβ‐positive individuals. However, the link between GFAP and tau PET in individuals without detectable Aβ pathology remains elusive. The aim of the current study is to investigate the association between plasma GFAP and tau PET in CU Aβ PET‐negative individuals. Method We studied 147 CU Aβ PET‐negative participants from the HEAD cohort with plasma GFAP and p ‐tau217, as well as tau PET Flortaucipir and MK6240 data. Aβ positivity was determined by Aβ PET visual reading and Centiloid 12. Voxel‐wise linear regression models adjusted for age and sex tested the association of plasma GFAP and p ‐tau217 with tau PET. Further, the associations of plasma GFAP with peak tau PET SUVR values extracted from voxel‐wise association were fitted with a linear regression model adjusted for age and sex. Result Voxel‐wise analysis showed that plasma GFAP levels, but not plasma p ‐tau217 levels, were associated with tau PET in the medial temporal lobe (e.g., amygdala, entorhinal cortex, hippocampus) predominantly for Flortaucipir tau PET [Figure 1A, B, C, D]. The association between plasma p ‐tau217 and tau PET was weak in Aβ‐negative individuals. These results were similar when Aβ positivity was defined based on Centiloid 12. Furthermore, plasma GFAP and peak tau PET SUVR of Flortaucipir showed stronger association than that of MK6240 [Flortaucipir: β=0.4017, p <0.0001; MK6240: β=0.194, p = 0.0424; Figure 2A, B]. Conclusion We found an association between GFAP levels and tau PET uptake in individuals not expected to exhibit high levels of tau tangle‐related tracer uptake. Further analysis will be designed to elucidate the underpinning of this association, which could represent low levels of tau pathology, astrogliosis, or other factors.